B of A Securities analyst Brad Sills downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Neutral and announces $16 price target.
Citius Pharma’s ‘Antibiotic Lock’ Effective In Patients With Catheter-Associated Bloodstream Infections
Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infections, show significant improvement in time to catheter failure and overall treatment success.